Research Collaboration and License Agreement - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Research Collaboration And License Agreement [Line Items]
Performance obligation transaction price		$ 27,000		$ 27,000
Revenue from contract with customer excluding assessed tax		0	$ 867	0	$ 2,878
Based on License [Member]
Research Collaboration And License Agreement [Line Items]
Performance obligation transaction price		25,600		25,600
Based on Research Activities [Member]
Research Collaboration And License Agreement [Line Items]
Performance obligation transaction price		1,400		1,400
Early Development and Regulatory Milestones [Member]
Research Collaboration And License Agreement [Line Items]
Upfront of milestones payment				80,000
Non Early Stage Development Milestones [Member] | Non Exercise of Co-Funding And Co-Promotion Option [Member]
Research Collaboration And License Agreement [Line Items]
Upfront of milestones payment				165,000
Non Early Stage Development Milestones [Member] | Exercise of Co-Funding And Co-Promotion Option [Member]
Research Collaboration And License Agreement [Line Items]
Upfront of milestones payment				70,000
Specified Sales Based Milestones [Member]
Research Collaboration And License Agreement [Line Items]
Upfront of milestones payment				235,000
Pfizer [Member]
Research Collaboration And License Agreement [Line Items]
Upfront payment received	$ 15,000
Research and Development Agreement [Member]
Research Collaboration And License Agreement [Line Items]
Revenue from contract with customer excluding assessed tax		$ 0	$ 0	$ 0	$ 0